It has been proven in the latest years that the tau protein that can be found in the brain cells of people suffering from Alzheimer could form neurofibrillary tangles. It is still unclear how could those tau proteins be used, but some researchers are saying that people could be cured from Alzheimer using them.
William Thies states the importance of therapeutic targets in the fight against this dangerous malady. If we investigate more opportunities, the chances to find something useful are significantly increased. Those techniques can also teach us important things about Alzheimer’s evolution. Amyloidal changes in the brain happen early in the process of Alzheimer’s evolution. This is how we can use tau for decreasing the evolution of Alzheimer, or even stopping it later.
Bapineuzumab is an antibody in the phase 3 of testing, and it has been designed as a treatment for mild to moderate Alzheimer. The shospho-tau is an abnormal form of tau that could provoke severe lesions on the brain of people suffering from Alzheimer. Increased p-tau could lead to the developing cerebrospinal fluid (CSF) and also to active loss of brain cells. P-tau is studied also in the second phase of bapineuzumab trials.
Kaj Blennow from the Gothenburg University in Sweden reported that their pooled explanatory analysis came up with some surprising conclusions: the immunotherapy treatment against amloyid may also lead to loss of function. As this was a small study, some additional researches are required so those statements would be confirmed.
Brain inflammation symptoms were developed by 6 percent of people that participated to this study. Beta amyloidal was reduced in specifically dendryres. Tau cells could be found in tangles form. This is the explanation for people that participated in the first experiment couldn’t have an improvement of cognitive functioning.